Demand for Whole Plasmid Sequencing in USA (2025 - 2035)

Demand for Whole Plasmid Sequencing in USA Forecast and Outlook 2025 to 2035

The demand for whole plasmid sequencing in the USA is expected to grow from USD 222.7 million in 2025 to USD 519.4 million by 2035, reflecting a compound annual growth rate (CAGR) of 8.8%. Whole plasmid sequencing plays a crucial role in genomics and biotechnology, aiding in the analysis of plasmids, their gene content, and their applications in areas like genetic engineering, vaccine development, and synthetic biology. The increasing focus on biotechnology and life sciences research, coupled with advancements in sequencing technologies, is expected to drive the steady demand for whole plasmid sequencing over the forecast period.

The market will experience consistent growth, starting at USD 222.7 million in 2025 and increasing to USD 242.4 million in 2026, USD 263.8 million in 2027, and USD 287.1 million in 2028. By 2029, the demand for whole plasmid sequencing will reach USD 312.5 million, continuing its upward trajectory through the 2030s. By 2035, the demand for whole plasmid sequencing is projected to reach USD 519.4 million, driven by ongoing advancements in biotechnology, the growing need for genetic research, and the increasing use of plasmids in various scientific and medical applications.

Quick Stats of the Demand for Whole Plasmid Sequencing in USA

• Demand for Whole Plasmid Sequencing in USA Value (2025): USD 222.7 million
• Demand for Whole Plasmid Sequencing in USA Forecast Value (2035): USD 519.4 million
• Demand for Whole Plasmid Sequencing in USA Forecast CAGR (2025 to 2035): 8.8%
• Demand for Whole Plasmid Sequencing in USA Key Product Type: 71.2% Consumables
• Demand for Whole Plasmid Sequencing in USA Key Growth Regions: West USA, South USA, Northeast USA, Midwest USA
• Demand for Whole Plasmid Sequencing in USA Key Players: Illumina, Inc., Thermo Fisher Scientific, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, BGI Genomics

What is the Growth Forecast for the Whole Plasmid Sequencing Industry in USA through 2035?

The half-decade weighted growth analysis for whole plasmid sequencing indicates significant contributions to overall market growth, particularly from 2025 to 2029. Over this period, the market will accumulate substantial value, with the growth rate remaining steady as the technology continues to mature and find new applications in genetic research and biotechnology. The weighted growth will be higher in the earlier part of the forecast period, reflecting increasing investments in sequencing technologies, adoption across research labs, and enhanced research funding.

From 2029 to 2035, the weighted growth will continue at a slightly more stable rate as the technology becomes more integrated into various biotechnological and medical research processes. The growth during this phase will be driven by increased use in genetic engineering, vaccine development, and the expanding role of plasmids in synthetic biology. The overall value accumulation over the next decade is substantial, indicating that whole plasmid sequencing will remain a critical tool in biotechnology and genomic research well into the future.

USA Whole Plasmid Sequencing Industry Key Takeaways

Metric	Value
Industry Sales Value (2025)	USD 222.7 million
Industry Forecast Value (2035)	USD 519.4 million
Industry Forecast CAGR (2025 to 2035)	8.8%

Why is the Demand for Whole Plasmid Sequencing in USA Growing?

Demand for whole plasmid sequencing in the USA is rising as biotechnology, gene therapy and synthetic biology research accelerate. Plasmids serve as vectors in gene cloning, expression systems, viral vector manufacturing, and gene editing workflows. Researchers and developers need to verify full plasmid sequence integrity, confirm absence of unintended mutations or rearrangements, and validate constructs - especially when these plasmids are destined for therapeutic or regulatory sensitive applications. As the volume of preclinical studies, gene therapy trials and biologics development increases, demand for comprehensive plasmid sequencing escalates accordingly.

At the same time advances in sequencing technologies and decreasing costs support broader adoption. Next generation sequencing platforms and long read sequencing systems allow complete plasmid characterization in a single run, offering higher accuracy and throughput than older fragment based methods. This makes whole plasmid sequencing more practical for routine use in academic labs, contract research organizations, and pharmaceutical companies. Growing emphasis on quality control, reproducibility, and regulatory compliance in genetic engineering and drug development further reinforces demand. As long as gene based research and therapies expand in the USA, demand for whole plasmid sequencing is likely to continue growing steadily.

What Is the Current State of the Demand for Whole Plasmid Sequencing in the USA in Terms of Sequencing Technique and Product Type?

The demand for whole plasmid sequencing in the USA is primarily driven by sequencing technique and product type. The leading sequencing technique is sequencing by synthesis, which accounts for 39% of the market share, while consumables dominate the product type segment, capturing 71.2% of the demand. Whole plasmid sequencing is a key method used in genetic research and biotechnology for analyzing plasmids, particularly in gene editing, cloning, and synthetic biology applications. As the demand for genetic research and biopharmaceutical innovations increases, the adoption of advanced sequencing techniques and high-quality consumables remains strong in the USA.

How Is Sequencing by Synthesis Leading the Demand for Whole Plasmid Sequencing in the USA?

Sequencing by synthesis leads the demand for whole plasmid sequencing in the USA, holding 39% of the market share. This technique involves reading the sequence of DNA bases as they are synthesized by incorporating fluorescently labeled nucleotides. Sequencing by synthesis is popular for its high accuracy and high-throughput capabilities, making it suitable for a wide range of applications, including plasmid sequencing. It enables researchers to analyze complex genetic sequences with high precision and is widely used in various fields such as genomics, gene therapy, and microbial research.

The demand for sequencing by synthesis is driven by its versatility and reliability in providing accurate sequencing data. With the increasing use of plasmid sequencing for genetic engineering, vaccine development, and microbiome research, sequencing by synthesis offers an efficient solution for generating high-quality data. The widespread availability of next-generation sequencing (NGS) platforms utilizing this technique further fuels its dominance, as researchers seek cost-effective, high-performance tools for plasmid sequencing. As biotechnology and genetic research continue to grow, sequencing by synthesis is expected to remain the leading technique in whole plasmid sequencing.

How Are Consumables Leading the Product Type Demand for Whole Plasmid Sequencing in the USA?

Consumables lead the product type demand for whole plasmid sequencing in the USA, accounting for 71.2% of the market share. Consumables include reagents, kits, and other materials required for sequencing processes, and they are essential to ensuring the accuracy and reliability of sequencing results. These consumables are necessary for the preparation and processing of samples, as well as for optimizing the sequencing workflows. In the context of whole plasmid sequencing, consumables are crucial for tasks such as DNA amplification, library preparation, and nucleotide sequencing.

The demand for consumables is driven by their critical role in the sequencing process and the increasing volume of sequencing projects across research institutions, biotechnology firms, and clinical laboratories. As sequencing technologies continue to advance, the need for high-quality, specialized consumables grows. The rise of personalized medicine, genetic research, and biopharmaceutical applications ensures that consumables will remain a dominant product in the whole plasmid sequencing market. With ongoing research and development in genomics, consumables are expected to continue to drive growth in this market segment in the USA.

What is the Summary of Demand for Whole Plasmid Sequencing in the USA?

Demand for whole plasmid sequencing in the USA is growing as biotechnology and gene therapy research expand. Plasmid DNA plays a key role in recombinant protein production, vaccine development, and gene editing. Researchers and biopharma companies increasingly rely on whole plasmid sequencing to ensure the integrity and accuracy of their plasmid constructs. As the demand for precision in gene therapy and synthetic biology increases, whole plasmid sequencing becomes more critical for verifying plasmid vectors and ensuring they are free from mutations and errors.

What are the Drivers of Demand for Whole Plasmid Sequencing in the USA?

Several factors drive the demand for whole plasmid sequencing. First, the rapid growth of gene therapy and vaccine development relies on precise plasmid sequencing to confirm vector integrity. Second, advancements in sequencing technology, such as longread sequencing, have made whole plasmid sequencing faster and more costeffective, making it accessible to more research labs. Third, increasing regulatory requirements for the validation of biopharmaceutical products and the need for highquality, accurate data are driving more labs and companies to invest in whole plasmid sequencing. Finally, the growing use of synthetic biology and microbial engineering in biotechnology also increases the need for precise plasmid verification.

What are the Restraints on Demand for Whole Plasmid Sequencing in the USA?

Despite growth, certain challenges limit demand for whole plasmid sequencing. One restraint is the high cost associated with advanced sequencing technologies, which can be prohibitive for smaller labs or projects. Another challenge is the technical expertise required to perform whole plasmid sequencing and analyze the data, which may limit its adoption in labs with fewer resources or staff. Furthermore, some labs may choose simpler or less expensive methods for plasmid verification, such as restriction enzyme mapping, instead of full sequencing. Finally, the time and resources required for full plasmid sequencing may be seen as unnecessary for some applications, leading to limited use.

What are the Key Trends Influencing Demand for Whole Plasmid Sequencing in the USA?

Key trends include increasing use of longread sequencing technologies, which allow for more accurate and comprehensive plasmid sequencing. This is expanding the range of applications for plasmid sequencing, particularly in gene therapy, synthetic biology, and vaccine development. Another trend is the growing trend of outsourcing sequencing services to specialized providers, as many smaller biotech companies and academic labs prefer to rely on experts in sequencing rather than developing inhouse capabilities. Additionally, as the need for regulatory compliance in drug development and gene therapy grows, the demand for accurate and comprehensive plasmid verification continues to rise. Finally, the increase in investments in gene editing and personalized medicine is driving demand for advanced plasmid sequencing services.

What is the Regional Demand Outlook for Whole Plasmid Sequencing in the USA?

The demand for whole plasmid sequencing (WPS) in the USA is expected to grow substantially across all major regions. The West leads with a projected CAGR of 10.2%, followed by the South at 9.1%. The Northeast shows a forecast CAGR of 8.1%, and the Midwest follows at 7.1%. These regional differences reflect variation in biotechnology research activity, clinical diagnostics uptake, academic and industrial genomics investment, and the presence of biotech hubs. Rising interest in genetic engineering, drug discovery, precision medicine, and biopharmaceutical development underpins the overall growth in WPS demand.

Region	CAGR (%)
West USA	10.2
South USA	9.1
Northeast USA	8.1
Midwest USA	7.1

What factors drive high demand for Whole Plasmid Sequencing in the West USA?

In the West USA, a projected 10.2% annual growth in demand for whole plasmid sequencing arises from a concentration of biotech firms, research universities, and biopharma companies. Whole plasmid sequencing enables comprehensive analysis of plasmid constructs, allowing researchers to confirm genetic modifications, detect unintended mutations, and verify construct integrity before deploying plasmids in experiments or therapeutic development. This is particularly relevant for gene therapy, synthetic biology, and antibiotic resistance research. The region’s expansion in research funding, start ups engaging in molecular cloning, and increasing clinical trials contribute to elevated WPS demand. Moreover, advances in sequencing technologies, including long read sequencing platforms that enable accurate full length plasmid reads, lower costs and reduced turnaround times encourage adoption. As a result, WPS becomes a routine quality control and verification step in many laboratories, sustaining robust growth in the West USA.

Why is demand for Whole Plasmid Sequencing increasing in the South USA?

The South USA shows an expected 9.1% CAGR for whole plasmid sequencing demand, driven by growing biotechnology activity, emerging research centres, and increasing contract research organizations (CROs). Institutions focusing on molecular biology, microbiology, and genetic engineering expand their capacity for plasmid based work such as recombinant protein expression, vaccine development, and synthetic biology. Whole plasmid sequencing provides assurance that plasmid sequences are correct and stable, which reduces experimental failures and improves reproducibility. With technological improvements making WPS more accessible and cost effective, more laboratories adopt it as part of standard workflows. The South’s rising number of biotech start ups and manufacturing linked research means demand for sequencing, plasmid validation, and plasmid storage support services steadily grows. These factors support a strong but slightly lower growth rate compared to the West region.

What supports steady growth of Whole Plasmid Sequencing in the Northeast USA?

In the Northeast USA, a forecast 8.1% CAGR in demand for whole plasmid sequencing reflects the region’s strong academic infrastructure, established universities, hospitals, and research institutions. Many of these institutions engage in advanced genetic research, gene therapy development, and microbiology studies where plasmid constructs are pivotal. Whole plasmid sequencing allows researchers to verify entire plasmid backbones, inserted genes, promoter regions and other regulatory elements-ensuring construct fidelity and avoiding unintended mutations that could affect results. As sequencing costs decline and turnaround times shorten, more labs integrate WPS into their standard plasmid validation processes. The region also benefits from collaborations between universities and biotech firms, increasing overall sequencing volume. Although growth is moderate compared to coastal research hubs, consistent institutional demand supports a stable increase in WPS adoption throughout the Northeast.

How is Whole Plasmid Sequencing demand evolving in the Midwest USA?

In the Midwest USA, demand for whole plasmid sequencing is projected to grow at 7.1% annually. This reflects gradual expansion of biotechnology research activity beyond traditional coastal hubs. Midwestern universities, agricultural biotech firms, and contract research laboratories increasingly engage in plasmid based cloning, gene expression studies, and synthetic biology projects. Whole plasmid sequencing serves as a critical quality control tool, ensuring plasmid integrity before further use in experiments or commercial applications. While the concentration of high throughput sequencing facilities may be lower compared to other regions, improvements in sequencing platforms, affordability, and remote access to sequencing services lower adoption barriers. As the biotech ecosystem in the Midwest expands, and as more laboratories recognize the value of full length plasmid verification, demand for WPS is expected to grow steadily, albeit more moderately than in coastal regions.

What is the Competitive Landscape for the Whole Plasmid Sequencing Market in the USA?

The market for whole plasmid sequencing in the USA grows in step with wider adoption of advanced sequencing technologies across biotechnology, synthetic biology, gene therapy, and research institutions. Increasing demand for complete plasmid verification-ensuring vector integrity, detecting mutations or rearrangements, and confirming correct constructs before downstream use-drives uptake of long read sequencing and high throughput workflows. Recent global market data shows the whole plasmid sequencing sector valued at about USD 636.2 million in 2025, with projected growth to roughly USD 1,548.2 million by 2035 at an estimated compound annual growth rate (CAGR) near 9.3%. The USA, as part of North America, remains a major contributor to this trend, supported by strong research funding, active biotech and pharmaceutical sectors, and growing use of plasmid based vectors for therapies, vaccines, and synthetic biology.

In this competitive space several established sequencing providers are prominent. Illumina, Inc. holds a leading share of approximately 25.2%. Other key competitors include Thermo Fisher Scientific, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, and BGI Genomics. These firms offer sequencing platforms and services that support plasmid sequencing through a mix of short read, long read, and hybrid approaches. Providers differ in their focus: some emphasise high throughput and cost efficiency for routine plasmid validation; others prioritise long-read accuracy and completeness to detect structural variants or complex plasmid architectures. Demand drivers include growth in gene therapy development, increasing plasmid-based research, and requirement for quality control in plasmid manufacturing. As sequencing costs fall and throughput rises, competition centers on read accuracy, turnaround time, cost per sample, bioinformatics support, and capacity to handle diverse plasmid sizes and complexities.

Key Players of the Whole Plasmid Sequencing Industry in USA

• Illumina, Inc.
• Thermo Fisher Scientific
• Pacific Biosciences (PacBio)
• Oxford Nanopore Technologies
• BGI Genomics

Scope of the Report

Items	Details
Quantitative Units	USD Million
Regions Covered	USA
Sequencing Technique	Sequencing by Synthesis, Nanopore Sequencing, Next-Generation Sequencing (NGS), Sanger Sequencing, Single-Molecule Real-Time Sequencing
Product Type	Consumables, Instruments
Application	Agricultural Genetics, Environmental Analysis, Forensics, Genomic Research, Medical Diagnosis
End-User	Biotechnology Companies, Clinical Laboratories, Pharmaceutical Companies, Research Institutions
Key Companies Profiled	Illumina, Inc., Thermo Fisher Scientific, Pacific Biosciences (PacBio), Oxford Nanopore Technologies, BGI Genomics
Additional Attributes	Dollar sales by sequencing technique and product type indicate strong demand for Next-Generation Sequencing (NGS) and consumables, particularly in genomic research and medical diagnosis applications. Biotechnology companies and research institutions are key end-users, while instruments play a vital role in the adoption of sequencing technologies. Leading companies like Illumina and Thermo Fisher Scientific dominate the market, offering advanced sequencing platforms and associated products. The market is expected to grow with the increasing demand for high-throughput sequencing in medical and research applications.

Key Segments in the Demand for Whole Plasmid Sequencing in USA

Sequencing Technique:

• Sequencing by Synthesis
• Nanopore Sequencing
• Next-Generation Sequencing (NGS)
• Sanger Sequencing
• Single-Molecule Real-Time Sequencing

Product Type:

• Consumables
• Instruments

Application:

• Agricultural Genetics
• Environmental Analysis
• Forensics
• Genomic Research
• Medical Diagnosis

End User:

• Biotechnology Companies
• Clinical Laboratories
• Pharmaceutical Companies
• Research Institutions

Region:

• Northeast USA
• West USA
• Midwest USA
• South USA